Tricyclic compounds as glycogen synthase kinase 3 (GSK3) inhibitors and uses thereof

US11203601B2 · kind B2 · utility

Assignees

• The Broad Institute, Inc. · US
• Biogen MA Inc. · US

Inventors

• Florence Fevrier Wagner · Ashland, US
• Michel Weiwer · Cambridge, US
• Arthur J. Campbell · Cambridge, US
• Joshua R. Sacher · Somerville, US
• Edward Holson · Newton, US
• Brian S. Lucas · Arlington, US
• TeYu Chen · Boston, US

Key dates

• Filing date: Apr 5, 2018
• Grant date: Dec 21, 2021
• Expiry date: Apr 5, 2038

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02P20/55
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure provides compounds of Formula (I), and salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The provided compounds may be useful for inhibiting kinases, e.g., glycogen synthase kinase 3 (GSK3). The provided compounds may be able to selectively inhibit GSK3a, as compared to GSK3P and/or other kinases. The present disclosure further provides pharmaceutical compositions, kits, and methods of use, each of which involve the compounds. The compounds, pharmaceutical compositions, and kits may be useful for treating diseases associated with aberrant activity of GSK3a (e.g., Fragile X syndrome, attention deficit hyperactivity disorder (ADHD), childhood seizure, intellectual disability, diabetes, acute myeloid leukemia (AML), autism, and psychiatric disorder).